Search Results - "Zaccarelli, M."

Unusual clinical manifestation and challenging serological interpretation of syphilis: insights from a case report by Magri, F, Donà, M. G, Panetta, C, Pontone, M, Pimpinelli, F, Cameli, N, Cristaudo, A, Zaccarelli, M, Latini, A

“…The clinical manifestations of recent syphilis can be variable, with typical and atypical patterns. Several conditions may cause atypical clinical aspects,…”
Get full text

Implications of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) epidemic for sexual behaviours of men who have sex with men by Latini, A, Donà, MG, Giuliani, M, Magri, F, Zaccarelli, M

Get full text

Liver stiffness reduction and serum fibrosis score improvement in HIV/hepatitis C virus‐coinfected patients treated with direct‐acting antivirals by Fabbri, G, Mastrorosa, I, Vergori, A, Timelli, L, Lorenzini, P, Zaccarelli, M, Cicalini, S, Bellagamba, R, Plazzi, MM, Mazzotta, V, Antinori, A, Ammassari, A

“…Objectives Only a few studies have addressed liver stiffness dynamics after hepatitis C virus (HCV) treatment in patients with HIV/HCV coinfection. The aim was…”
Get full text

Pre-existent NRTI and NNRTI resistance impacts on maintenance of virological suppression in HIV-1-infected patients who switch to a tenofovir/emtricitabine/rilpivirine single-tablet regimen by Armenia, D, Di Carlo, D, Calcagno, A, Vendemiati, G, Forbici, F, Bertoli, A, Berno, G, Carta, S, Continenza, F, Fedele, V, Bellagamba, R, Cicalini, S, Ammassari, A, Libertone, R, Zaccarelli, M, Ghisetti, V, Andreoni, M, Ceccherini-Silberstein, F, Bonora, S, Di Perri, G, Antinori, A, Perno, C F, Santoro, M M

“…To evaluate the maintenance of virological suppression (VS) in antiretroviral-treated HIV-1-suppressed patients switching to a…”
Get full text

Lower proportion of sustained virologic response and higher residual HCV viremia at the end of direct-acting antivirals treatment in HIV/HCV co-infected as compared with HCV mono-infected patients: meaning and correlates by Mastrorosa, I, Comandini, U.V, Ammassari, A, Fabbri, G, Garbuglia, A.R, Capobianchi, M.R, D’Offizi, G, Lionetti, R, Vergori, A, Giannetti, A, Antinori, A, Zaccarelli, M

Get full text

Maraviroc 150 mg daily plus lopinavir/ritonavir, a nucleoside/nucleotide reverse transcriptase inhibitor-sparing regimen for HIV-infected naive patients: 48-week final results of VEMAN study by Nozza, S., Galli, L., Antinori, A., Chiappetta, S., Mazzotta, F., Zaccarelli, M., Ottou, S., De Battista, D., Pogliaghi, M., Di Pietro, M., Malnati, M., Ripa, M., Bonora, S., Lazzarin, A.

“…Non-conventional strategies with nucleoside/nucleotide reverse transcriptase inhibitor-sparing regimens in antiretroviral naive human immunodeficiency virus…”
Get full text

Virological response and resistance profile in HIV‐1‐infected patients starting darunavir‐containing regimens by Armenia, D, Di Carlo, D, Maffongelli, G, Borghi, V, Alteri, C, Forbici, F, Bertoli, A, Gori, C, Giuliani, M, Nicastri, E, Zaccarelli, M, Pinnetti, C, Cicalini, S, D'Offizi, G, Ceccherini‐Silberstein, F, Mussini, C, Antinori, A, Andreoni, M, Perno, CF, Santoro, MM

“…Objectives We evaluated the virological response in patients starting a regimen based on darunavir/ritonavir (DRV/r), which is currently the most widely used…”
Get full text

Reduced risk of Efavirenz Discontinuation in Naïve Patients Starting First‐Line Antiretroviral Therapy with Single Tablet versus dual Tablet Regimen by Fabbiani, M, Zaccarelli, M, Latini, A, Sterrantino, G, D'Ettorre, G, Grima, P, Mondi, A, Rossetti, B, Borchi, B, Giuliani, M, Antinori, A, De Luca, A, Di Giambenedetto, S

“…Objectives Despite not being approved in Europe as first‐line therapy, the efavirenz (EFV)‐containing single tablet regimen (STR) is frequently used in…”
Get full text

Genotypic resistance profiles associated with virological failure to darunavir-containing regimens: a cross-sectional analysis by Sterrantino, G., Zaccarelli, M., Colao, G., Baldanti, F., Di Giambenedetto, S., Carli, T., Maggiolo, F., Zazzi, M.

“…Introduction This study aimed at defining protease (PR) resistance mutations associated with darunavir (DRV) failure and PR resistance evolution at DRV failure…”
Get full text

Effect of Suppressing HIV Viremia on the HIV Progression of Patients Undergoing a Genotype Resistance Test after Treatment Failure by Zaccarelli, M, Lorenzini, P, Tozzi, V, Forbici, F, Ceccherini-Silberstein, F, Gori, C, D'Arrigo, R, Trotta, M. P, Narciso, P, Perno, C. F, Antinori, A

“…Background: Treatment guidelines for multi-experienced HIV patients have recently evolved from aiming to preserve immunity to achieving virological success,…”
Get full text

Evidence of Dual Sexual Transmission of Multi-resistant HIV with Two Years Persistence of Resistance to NRTI and NNRTI: a Case Report by Zaccarelli, M., Marconi, P., Visco-Comandini, U., Liuzzi, G., Sette, P., Acinapura, R., Mosti, S., Ammassari, A., Perno, C. F., Antinori, A.

“…A case report of dual sexual transmission, with secondary transmission from naïve to naïve patient, of HIV harbouring K103N and L100I mutations, conferring…”
Get full text

Observational study on HIV-infected subjects failing HAART receiving tenofovir plus didanosine as NRTI backbone by Bongiovanni, M, Gianotti, N, Chiesa, E, Nasta, P, Cicconi, P, Capetti, A, di Biagio, A, Matti, A, Tirelli, V, Marconi, P, de Luca, A, Mussini, C, Gatti, F, Zaccarelli, M, Abeli, C, Torti, C, Antinori, A, Castagna, A, d'Arminio Monforte, A

“…We evaluated the efficacy of tenofovir (TDF) - and didanosine (ddI)-containing backbones in HIV-infected experienced subjects. We included in the study 245…”
Get full text

Factors related to virologic failure among HIV-positive injecting drug users treated with combination antiretroviral therapy including two nucleoside reverse transcriptase inhibitors and nevirapine by Zaccarelli, M, Barracchini, A, De Longis, P, Perno, C F, Soldani, F, Liuzzi, G, Serraino, D, Ippolito, G, Antinori, A

“…Treatment strategies in human immunodeficiency virus (HIV)-positive active injecting drug users (IDUs) must take into account their lifestyles, that often…”
Get more information

Risk factors for overdose mortality: a case-control study within a cohort of intravenous drug users by Davoli, M, Perucci, C A, Forastiere, F, Doyle, P, Rapiti, E, Zaccarelli, M, Abeni, D D

“…Overdose mortality is the major adverse health effect of drug injection. The potential determinants of overdose death are poorly understood; the aim of this…”
Get more information

Acute hepatitis B by sexual transmission after interruption of lamivudine-containing antiretroviral regimen by LIUZZI, Giuseppina, ZACCARELLI, Mauro, SETTE, Pietro, GRISETTI, Susanna, ALBA, Lucia, ANTINORI, Andrea

“…Lamivudine was demonstrated to be a potent inhibitor of hepatitis B virus (HBV) replication. Since the first quarter of the year 2000, lamivudine has been…”
Get full text

Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients by MOCROFT, Amanda, KIRK, Ole, REISS, Peter, DE WIT, Stephane, SEDLACEK, Dalibor, BENIOWSKI, Marek, GATELL, Jose, PHILLIPS, Andrew N, LEDERGERBER, Bruno, LUNDGREN, Jens D

“…Chronic kidney disease (CKD) in HIV-positive persons might be caused by both HIV and traditional or non-HIV-related factors. Our objective was to investigate…”
Get full text

Dynamics of Viral Load in Plasma and HIV DNA in Lymphocytes During Highly Active Antiretroviral Therapy (HAART): High Viral Burden in Macrophages after 1 Year of Treatment by Garbuglia, A.R., Zaccarelli, M., Calcaterra, S., Cappiello, G., Marini, R., Benedetto, A.

“…In this study we evaluated the level of HIV RNA in plasma and HIV DNA in peripheral blood cells. Sixteen antiretroviral-experienced HIV patients with severe…”
Get full text

Liver-related death among HIV/hepatitis C virus-co-infected individuals: implications for the era of directly acting antivirals by Grint, Daniel, Peters, Lars, Rockstroh, Juergen K, Rakmanova, Aza, Trofimova, Tatiana, Lacombe, Karine, Karpov, Igor, Galli, Massimo, Domingo, Pere, Kirk, Ole, Lundgren, Jens D, Mocroft, Amanda

“…BACKGROUND:Potent, less toxic, directly acting antivirals (DAAs) for treatment of hepatitis C virus (HCV) infection promise to improve HCV cure rates among…”
Get full text

Effectiveness and Safety of Interferon-Free Direct-Acting Antiviral Hepatitis C Virus Therapy in HIV/Hepatitis C Virus Coinfected Individuals: Results From a Pan-European Study by Amele, Sarah, Peters, Lars, Rodger, Alison, Lundgren, Jens, Rockstroh, Jurgen, Matulionyte, Raimonda, Leen, Clifford, Jabłonowska, Elzbieta, Østergaard, Lars, Bhagani, Sanjay, Sarcletti, Mario, Clarke, Amanda, Falconer, Karolin, Wandeler, Gilles, Domingo, Pere, Maltez, Fernando, Zaccarelli, Mauro, Chkhartisvili, Nikoloz, Szlavik, Janos, Stephan, Christoph, Fonquernie, Laurent, Aho, Inka, Mocroft, Amanda

“…To investigate the effectiveness, safety, and reasons for premature discontinuation of direct-acting antivirals (DAAs) in a diverse population of HIV/hepatitis…”
Get full text

HIV infection among foreign people involved in HIV-related risk activities and attending an HIV reference centre in Rome: The possible role of counselling in reducing risk behaviour by SPIZZICHINO, L., CASELLA, P., ZACCARELLI, M., REZZA, G., VENEZIA, S., GATTARI, P.

“…Between September 1993 and December 1995, 528 foreign individuals at risk of HIV infection attended the drug treatment centre located in the Santo Spirito…”
Get full text